Avosentan (Standard)

Overview

Avosentan (Standard) is the analytical standard of Avosentan ( HY-15195 ). This product is intended for research and analytical applications. Avosentan is an orally active endothelin ( ETA ) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > Endothelin Receptor

Product Information

• Catalog No.: HY-15195R
• CAS No.: 290815-26-8
• Molecular Formula: C23H21N5O5S
• Molecular Weight: 479.51
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source